Last Updated 19 December 2013
The malignant melanoma market has undergone significant changes in the last two years owing to the launch of three targeted therapies and one immunotherapy for treatment of unresectable or metastatic disease. The launch of vemurafenib (Roche/Genentech/Daiichi Sankyo/Chugai’s Zelboraf) in the United States and Europe for patients with a BRAF V600 mutation quickly resulted in the segmentation of the unresectable and metastatic patient population by BRAF mutation status. The subsequent launches of dabrafenib in the United States and Europe and of trametinib in the United States for the same patient population—and ongoing development of targeted agents for this segment—will ensure that this clinical practice continues. The expected launch of novel immunotherapies will further increase the competition for patient share across the unresectable and metastatic market, and emerging therapies will need to differentiate and position themselves to gain maximum traction in this small indication.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 26 country-specific interviews with thought leaders. We also surveyed malignant melanoma specialists (including dermatologists) in each market on their treatment practices.
Epidemiology: Diagnosed incidence of malignant melanoma by stage of disease and resectability. Clinical- and market-relevant drug-treatable populations.
Population segments in market forecast: Resectable (stage II-III), first-line unresectable BRAF-mutation-negative, first-line unresectable BRAF-mutation-positive, second-line unresectable BRAF-mutation-negative, second-line unresectable BRAF-mutation-positive, third-line unresectable BRAF-mutation-negative, third-line unresectable BRAF mutation-negative.
Emerging therapies: Phase II: 15 drugs; Phase III: 11 drugs.